Roche Secures CE Mark for Elecsys NfL Blood Test to Monitor Multiple Sclerosis Neuroinflammation
BASEL, Switzerland — Roche announced on Monday, April 13, 2026, that its Elecsys Neurofilament Light Chain (NfL) test has received CE mark approval. The minimally invasive blood test is designed to detect neuroinflammation in adult patients diagnosed with relapsing-remitting multiple sclerosis (RRMS).
The Elecsys NfL blood test functions as an in vitro quantitative immunoassay, measuring the levels of NfL protein in human serum and plasma. NfL is a protein released into the bloodstream during nerve cell injury, serving as a biological marker for neuroaxonal damage. By quantifying this protein, clinicians can gain a clearer picture of the neuroinflammatory activity occurring within the central nervous system.
Improving Access to Disease Monitoring
For the more than 2.9 million people worldwide living with multiple sclerosis, regular monitoring of disease activity is essential for optimizing treatment. However, the current standard of care often relies on routine assessments such as MRI scanning. Many patients face significant barriers to accessing these scans, which can delay the detection of changes in their condition.
The Elecsys NfL test offers a different diagnostic pathway. Since it requires only a simple blood draw, it provides greater patient access to monitoring compared to traditional methods. While it does not replace MRI or clinical assessments, it complements them by providing biological insights into nerve damage, potentially allowing for earlier clinical intervention and better-informed disease management.
Regulatory Timeline and FDA Status
The CE mark approval marks a significant step in the commercial availability of the test. This follows previous regulatory momentum in the United States. In November 2023, the U.S. Food and Drug Administration (FDA) granted the Elecsys NfL test Breakthrough Device Designation.
The FDA designation is intended to accelerate the development of products that more effectively diagnose or treat life-threatening diseases. At the time of the designation, the test was believed to assist in detecting disease activity in adults between the ages of 18 and 55 with relapsing types of MS, including both RRMS and secondary progressive MS (SPMS). This status provided Roche with priority review and more frequent interactions with FDA experts to advance the technology.
According to Roche Diagnostics, the goal of the test is to support better disease management decisions by providing rapid results through a minimally invasive process.
The Clinical Impact of NfL Measurement
Multiple sclerosis occurs when the immune system attacks the myelin sheath—the protective fatty coating around nerve fibers. This process, known as demyelination, impairs nerve function and leads to a wide range of symptoms. When these nerve cells are injured, NfL is released into the cerebrospinal fluid and subsequently the blood.
By measuring these levels, clinicians can monitor the biological damage caused by the disease more frequently than is typically possible with imaging. This capability is particularly critical for patients with RRMS, where identifying spikes in neuroinflammation early can lead to rapid adjustments in management approaches.
Key Technical and Regulatory Details
| Feature | Detail |
|---|---|
| Test Name | Elecsys Neurofilament Light Chain (NfL) |
| Methodology | In vitro quantitative immunoassay |
| Sample Type | Human serum and plasma |
| CE Mark Date | April 13, 2026 |
| FDA Status | Breakthrough Device Designation (Nov 2023) |
| Primary Indication | Neuroinflammation in adults with RRMS |
Looking Ahead
The introduction of the Elecsys NfL test into clinical practice represents a shift toward biomarker-driven monitoring in MS care. By reducing the reliance on high-cost, low-accessibility imaging for every check-up, the medical community may be able to implement more regular and precise tracking of patient health.
Roche (SIX: RO, ROP; OTCQX: RHHBY) continues to integrate these insights into the broader landscape of MS disease management, aiming to bridge the gap between clinical symptoms and biological reality.
The next confirmed checkpoint for the technology will be its expanded rollout across European markets following the CE mark approval. Further updates on U.S. FDA clearance status are expected as the company continues its regulatory process.
Do you think minimally invasive biomarkers will eventually replace imaging as the primary tool for monitoring chronic neurological diseases? Share your thoughts in the comments below.
